PrEP is likely to be cost-effective, regardless of which regimen, or which route, is used. Here: the latest from CROI.
A new study suggests that cognitive impairments in older HIV-infected individuals may be even more prevalent than previously thought.
Do you know which patients would benefit from PrEP? The CDC reports that many American adults who could benefit from HIV prophylaxis aren't receiving treatment.
Here's why you need to keep bone disease in mind when choosing an antiretroviral regimen for your patients with HIV -- and guidance about selecting therapy.
Depression is a major barrier to HIV care. But depression treatment can significantly reduce depressive severity--and improve HIV outcomes. Details here.
News from the CDC: men who have sex with men should be targeted for high-frequency HIV testing.
More than 22 million people living with HIV are not being treated. New WHO guidelines call for treatment for every one of these people--regardless of their CD4 cell count.
A new study finds that many children with perinatal HIV infection lack sufficient immunity to combat measles, mumps, and rubella--even though they may have received the MMR vaccine.
An increasing number of older AIDS patients are starting antiretroviral therapy. Maximum survival benefit is realized when ART is initiated when CD4 counts are high--regardless of the patient's age, according to a new study.
Clinically significant drug interactions involving antiretroviral agents have been reported in 30% to 40% of HIV-positive patients in the USA. However, this study finds that just a few therapeutic groups are responsible for most of the interactions detected.
Vitamin D and calcium supplementation is a low-cost, well-tolerated intervention to prevent ART-related bone loss, according to a new study.
Here's compelling evidence that a screening program in primary care leads to an increased rate of HIV diagnosis.
Previous studies have established that early treatment of HIV dramatically reduces the odds of spreading the infection to a sexual partner. The START trial provides evidence that early therapy benefits a patient's own health.
Interest in preexposure prophylaxis is high among a diverse population of men who have sex with men who are at risk for HIV infection.
A large increase in HIV and HCV infections in Indiana among injection drug users has prompted the CDC to issue a nationwide public health alert. Here's what you can do.